Gastric Neoplasm

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Identification of an oncogenic mutation in FGFR4 in a human gastric tumour that leads to constitutive activation and sensitivity to ASP5878.

PMID 31601997 · Futami et al., 2019 · Open in CIViC

HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear e… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

This study identified a recurrent MALAT1::GLI1 fusion in 4 of 4 (100%) gastroblastomas from patients ranging in age from 9 to 56 years old. Initially, the fusion was identified using transcriptome seq… (full text at CIViC)

PMID 37165307 · Hamada et al., 2023 · Open in CIViC

In this 2017 study the authors included four cases of gastroblastoma with control cases of histologic mimics. Gastroblastoma patients were aged 9, 27, 28 and 56 years. RNASeq identified a MALAT1::GLI1… (full text at CIViC)

PMID 28731043 · Graham et al., 2017 · Open in CIViC

Cabozantinib's effect on cell proliferation was studied in a variety of cell lines. In two gastric adenocarcinoma cell lines with MET amplification (SNU-5 and Hs746T) were the most sensitive to caboz… (full text at CIViC)

PMID 21926191 · Yakes et al., 2011 · Open in CIViC

A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response … (full text at CIViC)

PMID 22389872 · Catenacci et al., 2011 · Open in CIViC

4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against crizotinib, which showed… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

4 patient-derived cell lines with MET exon 14 skipping mutation were selected from 50 patient derived tumor lines from the SMC Biomarker study. These cell lines tested against SAIT301, a monoclonal an… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarc… (full text at CIViC)

PMID 28958504 · Catenacci et al., 2017 · Open in CIViC

46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were… (full text at CIViC)

PMID 27313181 · Rokutan et al., 2016 · Open in CIViC

The methylation status of MLH1 was analyzed in a study of 53 paraffin-embedded gastric cancer samples. No association was found between methylation status and clinical factors. The study showed that M… (full text at CIViC)

PMID 24748501 · Li et al., 2015 · Open in CIViC

The MTHFR C667T variant was associated with significantly lower relapse-free survival and overall survival in stomach cancer patients treated with 5-Fluorouracil-based therapies. 116 Chinese patients … (full text at CIViC)

PMID 18704422 · Huang et al., 2009 · Open in CIViC

A 27-year old male patient displayed poorly differentiated gastric adenocarcinoma and massive malignant ascites. Shortly after his diagnosis, the patient died. After genomic sequencing, it was shown t… (full text at CIViC)

PMID 26375439 · Lee et al., 2015 · Open in CIViC

In preclinical gastric carcinoma models, NPTXR overexpression conferred sensitivity to NPTXR-targeted therapy. In xenograft mouse models of gastric cancer (MKN1; n = 3–4 mice per group), treatment wi… (full text at CIViC)

PMID 32847597 · Kanda et al., 2020 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.

PMID 22292935 · Shi et al., 2012 · Open in CIViC

474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 resp… (full text at CIViC)

PMID 24608574 · Fritsch et al., 2014 · Open in CIViC

In a panel of 20 gastric cancer cell lines, the line that showed greatest sensitivity to AZD5363 in MTS cell proliferation assay contained both PIK3CA E542K and PTEN Loss.

PMID 24088382 · Li et al., 2013 · Open in CIViC

In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mo… (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched i… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the … (full text at CIViC)

PMID 24088382 · Li et al., 2013 · Open in CIViC

Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-… (full text at CIViC)

PMID 15900596 · Oki et al., 2005 · Open in CIViC

285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles. RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognos… (full text at CIViC)

PMID 27313181 · Rokutan et al., 2016 · Open in CIViC

Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC)

PMID 28028034 · Kim et al., 2017 · Open in CIViC

54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser24… (full text at CIViC)

PMID 22343617 · Yoon et al., 2012 · Open in CIViC

The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC)

PMID 28002800 · Xu et al., 2017 · Open in CIViC

In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC)

PMID 24740294 · Xu et al., 2014 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater t… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC)

PMID 14514923 · Bataille et al., 2003 · Open in CIViC

In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).

PMID 22422354 · Shen et al., 2012 · Open in CIViC

Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% C… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC

In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC)

PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC